Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
97%
Isoprenoid
67%
Farnesyl Trans Transferase
62%
Bisphosphonic Acid Derivative
43%
Lenalidomide
40%
Myeloma
29%
Triazole
29%
Malignant Neoplasm
19%
Mevinolin
16%
Clinical Trial
15%
Geranylgeranyl Pyrophosphate
15%
Bortezomib
15%
Disease
14%
Alkene
12%
Daratumumab
12%
Dexamethasone
11%
Tropolone
11%
Thalidomide
11%
Overall Survival
10%
Geranyltransferase
10%
Synthetase
8%
Placebo
8%
Minimal Residual Disease
8%
Progression Free Survival
7%
Proteasome Inhibitor
7%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Triazole Derivative
6%
Monoclonal Antibody
6%
Bone Disease
6%
Leukemia
6%
Chronic Myeloid Leukemia
5%
Imatinib
5%
Acute Myeloid Leukemia
5%
Adverse Event
5%
Phosphonate
5%
Rab Protein
5%
Drug Delivery System
5%
Transferase
5%
Keyphrases
Multiple Myeloma
56%
Geranylgeranyl Diphosphate Synthase
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Triazole
23%
Bisphosphonates
23%
Myeloma
19%
Isoprenoids
18%
Lenalidomide
17%
Isoprenoid Pathway
14%
Minimal Residual Disease
13%
Maintenance Therapy
13%
Newly Diagnosed multiple Myeloma
13%
Transplant Eligibility
12%
Daratumumab
11%
Marrow Transplantation
11%
Immune Profiling
11%
Disease Profiling
11%
Clinical Trials Network
11%
Griffin
11%
Olefins
10%
Myeloma Cells
10%
Newly Diagnosed
9%
Bortezomib
9%
Farnesyl Pyrophosphate
8%
Osteosarcoma
8%
Pathway Inhibitors
8%
Geranylgeranyl Pyrophosphate
8%
Geranylgeranylation
8%
Overall Survival
7%
Acute Myeloid Leukemia
7%
Lovastatin
7%
Older Adults
7%
International Myeloma Working Group
7%
Pyrophosphate Analog
7%
Tropolone
7%
Relapsed or Refractory multiple Myeloma
7%
GGDP Synthase
6%
Lenalidomide Maintenance
6%
Protein Secretion
6%
Unfolded Protein Response
6%
Confidence Interval
6%
Progression-free Survival
5%
Protein Geranylgeranylation
5%
Geranylgeranyl
5%
Medicine and Dentistry
Multiple Myeloma
100%
Transplantation
34%
Myeloma
34%
Lenalidomide
33%
Minimal Residual Disease
28%
Clinical Trial
26%
Maintenance Therapy
25%
Stem Cell Transplant
24%
Autologous Stem Cell Transplantation
20%
Disease
14%
Malignant Neoplasm
12%
Daratumumab
10%
Oncology
9%
Overall Survival
9%
Monoclonal Antibody
8%
Disease Assessment
8%
Acute Myeloid Leukemia
7%
Tyrosine-Kinase Inhibitor
7%
Plasma Cell
7%
B Cell Maturation Antigen
7%
Placebo
7%
Dexamethasone
6%
Progression Free Survival
6%
Proteasome Inhibitor
6%
Patient Population
5%
Clinical Trial Design
5%
Bortezomib
5%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%
Immunomodulatory Drug
5%
Hematology
5%
